AR007897A1 - Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene. - Google Patents

Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene.

Info

Publication number
AR007897A1
AR007897A1 ARP970103182A ARP970103182A AR007897A1 AR 007897 A1 AR007897 A1 AR 007897A1 AR P970103182 A ARP970103182 A AR P970103182A AR P970103182 A ARP970103182 A AR P970103182A AR 007897 A1 AR007897 A1 AR 007897A1
Authority
AR
Argentina
Prior art keywords
medicinal product
independently
piperidine
lower alkyl
hydroxy
Prior art date
Application number
ARP970103182A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR007897A1 publication Critical patent/AR007897A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Un compuesto derivado de la 4-hidroxi-piperidina, de fórmula I en donde X es -O-, -NH-, -CH2-, -CH=, CO2-, -CONH-, -CON (alquilo inferior)-, -S-, Y -SO2-; R1-R4 son independientemente entre sí, hidrógeno, halógeno, hidroxilo, amino, nitro, alquiloinferior-sulfonilamino, 1- o 2-imidazolilo, 1-(1,2,4-triazolil)o acetamido; R5, R6 son, independientemente entre sí, hidrógeno, alquilo inferior, hidroxilo, alcoxilo inferior u oxo; R7, R10 son independientementeentre sí, hidrógeno, alquilo inferior, halógeno, trifluorometilo o alcoxilo inferior; n es 0 o 1; y las sales de adición ácida farmacéuticamente aceptablesde los mismos; su empleo para el tratamiento de enfermedades, un procedimiento para prepararlo y un medicamento que lo contiene. Los compuestos de fórmula Iy sus sales se distinguen por sus valiosas propiedades terapéuticas. Los compuestos de la presente invención son bloqueadores selectivos de los subtiposde receptores del NMDA (N-metil-Daspartato), loscuales tienen una función clave en la actividad y plasticidad neuronal lo cual hace que jueguen un papelbásico en los procesos de mediación que subyacen en el desarrollo del CNS (Sistema nervioso central) así como en la formación de la capacidad deaprendery la memoria.
ARP970103182A 1996-07-19 1997-07-16 Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene. AR007897A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96111660 1996-07-19
EP97105366 1997-04-01

Publications (1)

Publication Number Publication Date
AR007897A1 true AR007897A1 (es) 1999-11-24

Family

ID=26142078

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970103183A AR007898A1 (es) 1996-07-19 1997-07-16 Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene.
ARP970103182A AR007897A1 (es) 1996-07-19 1997-07-16 Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP970103183A AR007898A1 (es) 1996-07-19 1997-07-16 Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene.

Country Status (34)

Country Link
US (1) US5889026A (es)
EP (1) EP0824098B1 (es)
JP (1) JP3179050B2 (es)
KR (1) KR100235804B1 (es)
CN (1) CN1120154C (es)
AR (2) AR007898A1 (es)
AT (1) ATE207899T1 (es)
AU (1) AU719352B2 (es)
BR (1) BR9704031A (es)
CA (1) CA2210044C (es)
CO (1) CO4900064A1 (es)
CZ (1) CZ290898B6 (es)
DE (1) DE69707782T2 (es)
DK (1) DK0824098T3 (es)
ES (1) ES2164967T3 (es)
HK (1) HK1009124A1 (es)
HR (1) HRP970394A2 (es)
HU (1) HUP9701194A3 (es)
ID (1) ID19632A (es)
IL (1) IL121299A (es)
MA (1) MA24274A1 (es)
MX (1) MX9705387A (es)
NO (1) NO308657B1 (es)
NZ (1) NZ328330A (es)
PE (1) PE86398A1 (es)
PL (1) PL321201A1 (es)
PT (1) PT824098E (es)
RU (1) RU2178412C2 (es)
SG (1) SG60085A1 (es)
TR (1) TR199700659A2 (es)
TW (1) TW498067B (es)
UY (1) UY24625A1 (es)
YU (1) YU30197A (es)
ZA (1) ZA976224B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6339087B1 (en) 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
MXPA00011889A (es) * 1998-06-02 2003-04-25 Osi Pharm Inc Composiciones de pirrolo (2,3d) piridina y su uso.
CO5150201A1 (es) * 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
BR9915735A (pt) 1998-11-20 2001-09-04 Hoffmann La Roche Antagonistas receptores de ccr-3 de piperidina
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
PA8525601A1 (es) * 2000-08-21 2002-04-25 Hoffmann La Roche Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
US6680324B2 (en) * 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7375136B2 (en) * 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
MXPA04000737A (es) * 2001-07-24 2004-07-08 Richter Gedeon Vegyeszet Derivados de piperidina como antagonistas receptores de nmda.
EP1450811B1 (en) * 2001-11-30 2009-10-21 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
CN1620294A (zh) 2001-12-20 2005-05-25 Osi药物公司 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
US6951884B2 (en) * 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
WO2005030720A1 (ja) * 2003-09-25 2005-04-07 Shionogi & Co., Ltd. Ｎｍｄａ受容体拮抗作用を有するピペリジン誘導体
CA2543287A1 (en) * 2003-10-23 2005-05-06 F.Hoffmann-La Roche Ag Benzazepine derivatives as mao-b inhibitors
HUP0401522A2 (en) * 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
US7485637B2 (en) * 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
US8420680B2 (en) * 2007-06-29 2013-04-16 Emory University NMDA receptor antagonists for neuroprotection
US7869022B2 (en) 2007-07-18 2011-01-11 Asml Netherlands B.V. Inspection method and apparatus lithographic apparatus, lithographic processing cell, device manufacturing method and distance measuring system
EP2296658A4 (en) * 2008-05-09 2014-01-15 Univ Emory ANTAGONISTS OF NMDA RECEPTORS USEFUL FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS
US7874106B2 (en) * 2009-02-13 2011-01-25 Ykk Corporation Of America Sill flashing and end dam assembly
BR112012009123A2 (pt) * 2009-10-19 2017-09-19 Amicus Therapeutics Inc novas composições para a prevenção e/ou tratamento de distúrbios de depósito lisossômico
ES2617192T3 (es) * 2009-10-19 2017-06-15 Amicus Therapeutics, Inc. Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2099339C1 (ru) * 1990-02-06 1997-12-20 Пфайзер Инк. Производные пиперидина
FR2672286B1 (fr) * 1991-01-31 1994-11-18 Synthelabo Derives de 1-(4-chlorophenyl)-2-[4-(phenylmethyl)piperidin-1-yl]ethanol, leur preparation et leur application en therapeutique.
FR2681319B1 (fr) * 1991-09-12 1995-02-17 Synthelabo Derives de 1-(phenoxyalkyl)piperidine, leur preparation et leur application en therapeutique.
TW281670B (es) * 1993-09-02 1996-07-21 Hoffmann La Roche
ATE183184T1 (de) * 1994-01-31 1999-08-15 Pfizer Neuroprotektive chroman verbindungen
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists

Also Published As

Publication number Publication date
ID19632A (id) 1998-07-23
CZ227497A3 (cs) 1998-02-18
DK0824098T3 (da) 2002-02-18
AR007898A1 (es) 1999-11-24
TW498067B (en) 2002-08-11
NZ328330A (en) 1998-05-27
NO973337D0 (no) 1997-07-18
HRP970394A2 (en) 1998-06-30
CA2210044C (en) 2006-02-14
CA2210044A1 (en) 1998-01-19
US5889026A (en) 1999-03-30
SG60085A1 (en) 1999-02-22
KR980009244A (ko) 1998-04-30
PT824098E (pt) 2002-04-29
BR9704031A (pt) 1998-12-29
DE69707782T2 (de) 2002-06-20
PE86398A1 (es) 1998-12-10
HU9701194D0 (en) 1997-09-29
EP0824098B1 (en) 2001-10-31
ZA976224B (en) 1998-01-19
YU30197A (sh) 1999-12-27
TR199700659A2 (xx) 1998-02-21
NO973337L (no) 1998-01-20
ATE207899T1 (de) 2001-11-15
CO4900064A1 (es) 2000-03-27
KR100235804B1 (ko) 1999-12-15
EP0824098A1 (en) 1998-02-18
MX9705387A (es) 1998-01-31
CN1171396A (zh) 1998-01-28
IL121299A0 (en) 1998-01-04
HUP9701194A2 (hu) 1999-05-28
ES2164967T3 (es) 2002-03-01
IL121299A (en) 2001-12-23
MA24274A1 (fr) 1998-04-01
UY24625A1 (es) 2000-12-29
JPH1067742A (ja) 1998-03-10
JP3179050B2 (ja) 2001-06-25
NO308657B1 (no) 2000-10-09
PL321201A1 (en) 1998-02-02
AU719352B2 (en) 2000-05-04
HUP9701194A3 (en) 1999-06-28
CN1120154C (zh) 2003-09-03
RU2178412C2 (ru) 2002-01-20
CZ290898B6 (cs) 2002-11-13
HK1009124A1 (en) 1999-05-28
DE69707782D1 (de) 2001-12-06
AU2875697A (en) 1998-01-29

Similar Documents

Publication Publication Date Title
AR007897A1 (es) Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene.
UY27592A1 (es) Nuevo uso
MXPA01004256A (es) N-arilamidas del acido antranilico y del acido tioantranilico.
AR035422A1 (es) Compuestos derivados de imidazol, un medicamento que contiene uno o mas de dichos compuestos, un proceso para la preparacion de dichos compuestos y uso de dichos compuestos.
RU94045155A (ru) Способы ингибирования болезни альцгеймера
AR029454A1 (es) Derivados de piperazina sustituidos, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
ES2160525B1 (es) Derivados de la 4-aroilpiperidina antagonistas de los receptores ccr-3
NZ514487A (en) Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
AU2001239331A1 (en) Derivatives of quinoline as alpha-2 antagonists
ATE57922T1 (de) Gegebenenfalls substituierte, 1-(2'-(bis-(phenyl)-methoxy>-aethyl)-4-(3'-(bisphenyl)-methoxy>- propyl)-piperazine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
PT757685E (pt) Novas amidas ciclicas como incrementadores de libertacao de neurotransmissores
RU94046141A (ru) Замещенные производные /арилалкоксибензил/ аминопропанамида, способы их получения, фармацевтическая композиция
HUP0003577A2 (hu) Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.
AR032601A1 (es) UN COMPUESTO DERIVADO DE QUINOLIN -4-IL, MEDICAMENTO QUE CONTIENE UNO O MAS DE DICHO COMPUESTO, PROCEDIMIENTO PARA LA PREPARACIoN DEL COMPUESTO Y EL USO DEL COMPUESTO
AR037221A1 (es) Compuestos derivados de piridina, uso de los mismos, un procedimiento para su preparacion y un medicamento que contiene uno o mas de dichos compuestos
KR102016120B1 (ko) 순수한 5-ht6 수용체 길항제, 아세틸콜린에스테라제 저해제 및 nmda 수용체 길항제의 3중 조합물
HUP9702246A2 (hu) 3,4-Difenil-krománok alkalmazása degeneratív agybetegségek kezelésére vagy megelőzésére szolgáló gyógyszerkészítmények ipari előállítására
CA3135409A1 (en) Pyrrolopyrimidine inhibitors of wild-type and mutant forms of lrrk2
HUP0301594A2 (hu) E-metanikotin diacilborkősav sóját tartalmazó gyógyászati készítmények és alkalmazásuk a központi idegrendszer rendellenességeinek kezelésére
HUP0100611A2 (hu) Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére
ES2240506T3 (es) Derivados de (2-azabiciclo (2,2,1) helpt-7-il) metanol como aginistas de los receptores nicotinicos de la acetilcolina.
CN109476696B (zh) 动物及人抗锥虫和抗利什曼原虫剂
DK557189A (da) 1,2,3,4-tetrahydro-1,9-acridindiaminer, deres fremstilling og anvendelse som laegemidler

Legal Events

Date Code Title Description
FG Grant, registration